Therapy News and Research

RSS

Additional data from ALS patients enrolled in confirmatory Phase III STAR trial announced

AVANIR Pharmaceuticals, Inc. today announced additional data from the subset of patients with amyotrophic lateral sclerosis (ALS) enrolled in the confirmatory Phase III STAR trial.

9 Dec 2009

Pacific Beach BioSciences signs licensing agreement with major pharmaceutical company

Pacific Beach BioSciences, Inc. today reported that it has granted non-exclusive rights to a large pharmaceutical company for the use of one of its anti-fungal compounds required for the manufacturing of a clinical stage product.

9 Dec 2009

DOTS has cured 36m People, prevented up to 8m TB deaths over 15 years, WHO says

Since the WHO developed Directly Observed Therapy, Short-course (DOTS) in 1994 for the treatment of tuberculosis, approximately 36 million people have successfully completed treatment and been cured over the past 15 years, according to new data released by the WHO on Tuesday, health-e reports (Thom, 12/8).

9 Dec 2009

Today's opinions and editorials

The language in our amendment is completely consistent with the Hyde Amendment, which in the 33 years since its passage has done nothing to inhibit private health insurers from offering abortion coverage. There is no reason to believe that a continuation of this policy would suddenly create undue hardship for the insurance industry — or for those who wish to use their private insurance to pay for an abortion (Rep. Bart Stupak, 12/8).

9 Dec 2009

USPTO grants CyDex Pharmaceuticals patent for Captisol

CyDex Pharmaceuticals, Inc., a specialty pharmaceutical company, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent to the company entitled “Sulfoalkyl Ether Cyclodextrin Compositions and Methods of Preparation Thereof.” This patent, along with other previously issued technology patents, will provide broader protection for CyDex’s Captisol® technology until 2028.

9 Dec 2009

Decision Resources reports increased uptake of TNF-alpha inhibitors for Crohn's disease

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that compared to last year's analysis of U.S. patient-level claims data, TNF-alpha inhibitors are being used more often to treat newly diagnosed patients suffering from Crohn's disease.

9 Dec 2009

Osteologix to file an European Marketing Application for its NB S101 strontium therapy

Osteologix Inc. announced today that the company anticipates that it will be prepared to file a marketing application in 2011 in the European Union for its proprietary second-generation strontium therapy, NB S101 (strontium malonate). If successful, this will be Osteologix' first marketing approval of NB S101 for the treatment of postmenopausal osteoporosis.

9 Dec 2009

Varian Medical Systems receives IDG's InfoWorld 100 Award for innovative use of IT

Zenprise, Inc., a provider of mobile management software, today announced its customer, Varian Medical Systems Inc., received IDG's InfoWorld 100 Award based on its deployment of the Zenprise MobileManager platform. The InfoWorld 100 Awards recognizes the top 100 most innovative uses of IT initiatives to further business goals.

9 Dec 2009

Novartis presents 6-month results from its EVEREST study for PCV

QLT Inc. welcomed the 6-month results from the Novartis-sponsored EVEREST study which were presented during a scientific review today by Novartis in Basel, Switzerland.

9 Dec 2009

Home health care workers’ compensation cases discharged prior to 'order-end date'

Thirty percent of the home health care workers’ compensation cases managed by Total Medical Solutions (TMS) were discharged prior to the “order-end date,” the last date the physician had anticipated that services would be required.

9 Dec 2009

BIOLASE Technology's Waterlase MD laser system receives FDA marketing clearance

BIOLASE Technology, Inc., the world's leading dental laser company, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its Waterlase MD™ laser system for removal of subgingival calculi to prevent and treat periodontitis, the greatest cause of tooth loss for adults over 35 and a condition impacting more than half of Americans over the age of 55, as reported by the American Academy of Periodontology (AAP).

9 Dec 2009

Clinical trial results demonstrate greater efficacy of nilotinib over imatinib for Ph+ CML

In a large clinical trial, nilotinib demonstrated greater efficacy over the current gold standard treatment, imatinib, in adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML) in the chronic phase.

9 Dec 2009

VERTICAL Phase II trial results for NHL released

The Takeda Oncology Company today reported data from a clinical trial evaluating a VELCADE based combination for patients with relapsed/refractory non-Hodgkin’s lymphoma (NHL).

9 Dec 2009

AHS annual meeting focuses on myeloma, says IMF

The International Myeloma Foundation (IMF)—supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians— says a large number of abstracts – nearly a quarter of the presentations submitted this year to the annual meeting of the American Society of Hematology (ASH) were for myeloma, with one being presented at the prestigious plenary session.

9 Dec 2009

2009 Ward Burdick Award for UAB Director

The director of the University of Alabama at Birmingham (UAB) Center for Metabolic Bone Disease has won the 2009 Ward Burdick Award for Distinguished Service to Clinical Pathology from the American Society for Clinical Pathology (ASCP).

9 Dec 2009

High-flow oxygen appears to be more effective in treating cluster headaches

Patients with a cluster headache, which is characterized by bouts of excruciating pain usually near the eye or temple, were more likely to report being pain-free within 15 minutes of treatment with high-flow oxygen than patients who received a placebo treatment, according to a study in the December 9 issue of JAMA.

9 Dec 2009

Recruitment complete in Oxagen's OC000459 IIb clinical trial for asthma

Oxagen Limited, a drug discovery and development company specializing in inflammation, today announced that the recruitment for its double blind, randomised, placebo controlled Phase IIb clinical trial in asthma with OC000459, its lead oral CRTH2 (DP2) antagonist, has now been completed.

9 Dec 2009

CSC's stem cell-derived motor neuron product for SMA receives FDA orphan drug designation

California Stem Cell, Inc. (CSC) and Families of Spinal Muscular Atrophy (FSMA) announced today that the FDA has granted orphan drug designation to MOTORGRAFT™, a stem cell-derived motor neuron product, for the treatment of Spinal Muscular Atrophy (SMA).

9 Dec 2009

European markets for Parkinson's disease therapeutics to reach $2.28 billion in 2015

The Parkinson's disease therapeutics market in 2008 amounted to over $1 billion in the European Union (EU), which includes total sales of carbidopa/levodopa, dopamine agonists, MAO-B inhibitors, COMT inhibitors and anticholinergics used for disease symptom relief.

9 Dec 2009

Experts call on Europe's policy makers to take urgent action against preventable strokes

A report launched today by experts from medical and patient communities calls on Europe's policy makers to take urgent action against preventable strokes that strike thousands of atrial fibrillation (AF) patients each year

9 Dec 2009

Therapy News and Research

Additional data from ALS patients enrolled in confirmatory Phase III STAR trial announced

Pacific Beach BioSciences signs licensing agreement with major pharmaceutical company

DOTS has cured 36m People, prevented up to 8m TB deaths over 15 years, WHO says

Today's opinions and editorials

USPTO grants CyDex Pharmaceuticals patent for Captisol

Decision Resources reports increased uptake of TNF-alpha inhibitors for Crohn's disease

Osteologix to file an European Marketing Application for its NB S101 strontium therapy

Varian Medical Systems receives IDG's InfoWorld 100 Award for innovative use of IT

Novartis presents 6-month results from its EVEREST study for PCV

Home health care workers’ compensation cases discharged prior to 'order-end date'

BIOLASE Technology's Waterlase MD laser system receives FDA marketing clearance

Clinical trial results demonstrate greater efficacy of nilotinib over imatinib for Ph+ CML

VERTICAL Phase II trial results for NHL released

AHS annual meeting focuses on myeloma, says IMF

2009 Ward Burdick Award for UAB Director

High-flow oxygen appears to be more effective in treating cluster headaches

Recruitment complete in Oxagen's OC000459 IIb clinical trial for asthma

CSC's stem cell-derived motor neuron product for SMA receives FDA orphan drug designation

European markets for Parkinson's disease therapeutics to reach $2.28 billion in 2015

Experts call on Europe's policy makers to take urgent action against preventable strokes

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News